top of page

No-Exam Term Life Insurance After Basal Cell Carcinoma: What Underwriting Usually Asks

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Basal cell carcinoma (BCC) is common and often highly treatable. For term life insurance, underwriters usually focus on whether treatment is complete and whether follow-up has been clear.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

BCC: Usually About Timing and Follow-Up

When it was treated and what treatment was used (excision/Mohs)

Whether margins were clear and follow-up has been normal

Any history of other cancers or multiple recent lesions

Basal cell carcinoma can sound like a big red flag, but underwriting often treats it differently than many other cancers because BCC is almost always non-metastatic - meaning it stays local and does not spread to lymph nodes or distant organs the way other malignancies can. Carriers generally classify it as a skin-only event, which is a distinct and more favorable underwriting bucket than systemic cancer history. That said, the anatomical location of the lesion still matters: a BCC on the trunk or arm is surgically simpler than one located near the eye (periocular) or on the nasal ala, where tissue planes are tighter and the margin of safe excision is narrower. Periocular and nasal alar lesions sometimes require more extensive reconstruction and longer follow-up, which underwriting may ask about separately from a straightforward truncal removal.

Expect questions about the date of diagnosis, the treatment method, and whether the pathology report confirmed clear margins. Mohs micrographic surgery is a common treatment method worth understanding: it removes tissue layer by layer, and after each layer is removed, the margins are examined under a microscope before the surgeon proceeds - this continues until the pathologist confirms the margins are free of tumor cells. When an underwriter asks whether clear margins were achieved, a Mohs procedure with confirmed clear margins is exactly the documented answer they are looking for, and having that pathology report available can accelerate the decision. If you are seeing a dermatologist for routine surveillance checks, that is typically viewed as an appropriate and expected follow-up plan rather than a sign of ongoing concern.

What can complicate underwriting is recency, repetition, or immune status. A single BCC removed years ago with clean follow-up looks very different from multiple lesions treated across a short timeframe, because carriers may ask how many separate BCCs you have had and over what period - recurrence frequency is used as a proxy for sun-damage severity and the level of ongoing skin surveillance your history requires. Immunosuppressed applicants - including solid organ transplant recipients taking tacrolimus or mycophenolate, and certain autoimmune patients on long-term immunosuppressive therapy - develop BCC at substantially higher rates than the general population, and their follow-up schedules and risk profiles are evaluated under different underwriting guidelines than immunocompetent applicants with an isolated BCC. If you fall into that category, be prepared for questions about your transplant history or underlying condition alongside the BCC history itself.

Be careful with quick quotes that do not ask any detail about the nature or timing of the skin cancer. A quote generated under a no-cancer-history assumption will not survive underwriting if your application and records show BCC - the carrier will re-examine the classification once pathology details are reviewed, and the outcome may differ from the initial quote. This does not mean the answer is a decline; it means the final offer reflects what underwriting actually found rather than what the automated tool assumed. The safest approach is to answer all skin cancer questions accurately at the quote stage so the initial offer is already grounded in your real history.

If you have the basic facts organized - treatment date, type of procedure such as standard excision versus Mohs, anatomical site, whether clear margins were confirmed, and whether you have had any additional BCCs since - you will usually get a faster decision and fewer follow-up requests from the carrier. Knowing whether you are immunocompetent or immunosuppressed is also useful context, because it will come up if the carrier has a follow-up question about your dermatology surveillance schedule. A dermatology follow-up note from within the past year showing no new lesions and no active treatment is often the single most helpful document you can provide alongside your application, because it gives the underwriter a current clinical picture rather than one anchored only to the original diagnosis date.

For a broader overview of no-exam term life and how accelerated underwriting works, see: https://www.careproinsurance.com/instant-term-life-insurance

Educational purposes only; this is not professional legal, medical, or tax guidance. Any numbers shown during the quoting process are preliminary and subject to change based on underwriting review.

Frequently Asked Questions

Can I get no-exam term life insurance after basal cell carcinoma?

Often, yes, depending on timing and whether treatment is complete. Carriers usually want confirmation of treatment details and follow-up. Underwriting applies and guidelines vary.

How long after BCC treatment should I wait to apply?

It depends on the carrier and how recent treatment was. Some may proceed once treatment is complete; others may want a short stability window and a clean follow-up.

Do carriers treat basal cell carcinoma the same as melanoma?

Not usually. BCC is often viewed as skin-only and highly treatable, while melanoma can involve different staging and risk. Carrier guidelines vary by diagnosis and history.

What documents might underwriting request for BCC?

Some carriers may ask for pathology details, treatment dates, or a dermatology follow-up note, especially if the diagnosis was recent or there were multiple lesions.

Will my premium automatically increase because of BCC?

Not always. Many applicants can still receive competitive rates depending on timing, follow-up, and overall health profile. Outcomes vary by carrier.

Does the location of the BCC on my body affect underwriting?

It can. Lesions in anatomically complex areas - such as near the eye or on the nose - may require more extensive surgery and follow-up than lesions on the trunk or limbs. Underwriters may ask about the site specifically because location influences the complexity of the surgical margin and the reconstruction involved.

What does it mean if a BCC had positive margins on the pathology report?

Positive or close margins mean tumor cells were found at or near the edge of the removed tissue, which typically requires additional excision or treatment before the case is considered resolved. Underwriting generally wants to see that margins were confirmed clear before finalizing a decision, so a positive-margin history may prompt questions about what follow-up treatment was done.

Does having an organ transplant change how BCC is underwritten?

Yes, it can. Transplant recipients on long-term immunosuppressive medications develop skin cancers at higher rates than the general population, and carriers may apply different underwriting guidelines - including more frequent dermatology surveillance requirements - when evaluating a BCC in the context of an immunosuppressed applicant.

Get Covered With The Right Plan

Basal cell carcinoma is often treated as a skin-only history, so underwriting usually comes down to timing, treatment completion, and clean follow-up.

Compare term life quotes

bottom of page